Don't expect AstraZeneca's olaparib verdict until January
This article was originally published in Scrip
Executive Summary
If anyone was expecting the FDA’s verdict this week on AstraZeneca's ovarian cancer drug olaparib, an oral inhibitor of polyadenosine 5-diphosphoribose polymerases, don’t hold your breath.